- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Amrutanjan Health Care Limited — Results, 12-08-2025: Integrated Filing- Financial
Amrutanjan Health Care Ltd (AMRUTANJAN) has posted strong financial results for the quarter ended June 30, 2025.
1. **Revenue Performance:** Total revenue from operations increased 12.31% year-over-year (YoY) to INR 94.05 Cr. Growth was primarily fueled by the OTC Products segment, which saw a robust rise, and the Women's Hygiene segment. The Beverages segment, however, experienced a decline in revenue.
2. **Profitability and EPS:** Net profit soared by an impressive 80.08% YoY to INR 8.31 Cr. This significant jump in profitability led to basic Earnings Per Share (EPS) climbing to INR 2.87 from INR 1.60, indicating strong margin expansion.
3. **Operational Costs:** Total expenses rose at a slower pace than revenue, up 6.52% YoY to INR 87.18 Cr. While employee benefits expense increased, the company saw a slight decrease in raw material costs and a notable reduction in advertisement and selling expenditure, suggesting improved operational efficiency.
4. **Key Metrics:** OTC Products significantly boosted profit, and the Women's Hygiene segment turned profitable from a prior loss. The Beverages segment continued to post losses, which widened during the quarter.
5. **Balance Sheet Health:** While detailed cash flow and balance sheet specifics for the quarter are not provided, the company reported total equity of INR 323.72 Cr, reflecting a stable financial position supporting future operations.
6. **Strategic Outlook:** The company has announced a board meeting on August 12, 2025, which approved these results. The 88th Annual General Meeting has been set for September 23, 2025, with September 16, 2025, fixed as the record date for final dividend payment and voting.
7. **Final Takeaway:** Amrutanjan's latest results showcase strong momentum, particularly in its core OTC and Women's Hygiene segments, driven by both revenue growth and enhanced cost management, painting a positive outlook for investors despite ongoing challenges in the Beverages unit.